Czechia· CZ-0239318
POLAPIX
A apixaban product, registered in Czechia by Warszawskie Zaklady Farmaceutyczne Polfa S.A., Varšava. The same ATC class is registered in 17 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Apixaban is registered in 17 of 19 countries.
Countries holding a registration under ATC B01AF02 (apixaban), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 10 of them publish a price we can compare per daily dose
Apixaban · ATC B01AF02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of apixaban costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $3.38 in France to $7.97 in Italy — a ×2.4 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Apixaban · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- IT Italy$7.97
- CH Switzerland$4.70
- FR France$3.38
The record
At a glance
SÚKL (Czech Republic)- Manufacturer
- Warszawskie Zaklady Farmaceutyczne Polfa S.A., Varšava
- Country
- Czechia (CZ)
- ATC code
- B01AF02
- ATC class
- Apixaban
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- August 24, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
398 interactions on record for apixaban.
Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Apixaban · interactions on record
398 records
- 133 severe
- 224 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
39 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B01AF02
Apixaban, as other registers publish it.
- PolandAbatixentSandoz GmbH
- PolandAbatixentSandoz GmbH
- NetherlandsAbatixent 2,5 mg filmomhulde tablettenSandoz B.V.
- NetherlandsAbatixent 5 mg filmomhulde tablettenSandoz B.V.
- GermanyAbidalo123 Acurae Pharma Gmbh
- PolandAboxomaKrka, d.d., Novo mesto d.o.o.
- PolandAboxomaKrka, d.d., Novo mesto d.o.o.
- CzechiaABOXOMAKrka, d.d., Novo mesto, Novo mesto
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd5241b7-fee6-47b7-b06e-3d168ea11d03 GET /v1/drugs/fd5241b7-fee6-47b7-b06e-3d168ea11d03?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "5MG",
"pack_size": "20",
"substance": "17381",
"cz_kod_sukl": "0239318",
"product_type": "CH",
"registration_state": "B",
"registration_number": "16/204/19-C"
}See everything about apixaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.